Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

How I treat patients with massive hemorrhage

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Research output: Contribution to journalLetterResearchpeer-review

  4. Yet another susceptibility variant for ALL: what's next?

    Research output: Contribution to journalComment/debateResearchpeer-review

  5. A small change makes a big difference in Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Massive hemorrhage is associated with coagulopathy and high mortality. The transfusion guidelines up to 2006 recommended that resuscitation of massive hemorrhage should occur in successive steps using crystalloids, colloids and red blood cells (RBC) in the early phase, and plasma and platelets in the late phase. With the introduction of the cell-based model of hemostasis in the mid 1990ties, our understanding of the hemostatic process and of coagulopathy has improved. This has contributed to a change in resuscitation strategy and transfusion therapy of massive hemorrhage along with an acceptance of the adequacy of whole blood hemostatic tests to monitor these patients. Thus, in 2005, a strategy aiming at avoiding coagulopathy by pro-active resuscitation with blood products in a balanced ratio of RBC:plasma:platelets was introduced and this has been reported to be associated with reduced mortality in observational studies. Concurrently, whole blood viscoelastic hemostatic assays (VHA) have gained acceptance by allowing a rapid and timely identification of coagulopathy along with enabling an individualized, goal-directed transfusion therapy. These strategies joined together seem beneficial for patient outcome, although final evidence on outcome from randomized controlled trials are lacking. We here present how we in Copenhagen and Houston, today, manage patients with massive hemorrhage.

Original languageEnglish
Issue number20
Pages (from-to)3052-8
Publication statusPublished - 7 Oct 2014

ID: 44608083